Wellington Management Group LLP Grows Stock Holdings in Cellebrite DI Ltd. $CLBT

Key Points

• Wellington Management increased its Cellebrite DI stake by 93.7% in the second quarter, holding 3.05 million shares worth approximately $44.5 million. Institutional investors collectively own 45.88% of CLBT.
• Analysts remain generally positive, with five Buy ratings and one Sell rating, though several firms lowered their price targets. The stock has a MarketBeat consensus rating of “Moderate Buy” and an average target of $16.70.
• CLBT opened at $11.94, well below its 52-week high of $19.98, while company insiders sold 329,658 shares worth about $5.0 million over the past 90 days.

Wellington Management Group LLP boosted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 93.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 3,049,904 shares of the company's stock after buying an additional 1,475,579 shares during the period. Wellington Management Group LLP owned 1.22% of Cellebrite DI worth $44,529,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of CLBT. Cooper Creek Partners Management LLC bought a new position in shares of Cellebrite DI in the third quarter worth about $55,999,000. Capital International Investors purchased a new position in Cellebrite DI in the 4th quarter worth approximately $41,073,000. Invesco Ltd. boosted its stake in Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company's stock worth $103,030,000 after purchasing an additional 2,054,644 shares during the period. Weiss Asset Management LP grew its holdings in Cellebrite DI by 3,485.3% during the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company's stock valued at $26,180,000 after buying an additional 1,846,851 shares in the last quarter. Finally, Artisan Partners Limited Partnership purchased a new stake in Cellebrite DI during the 4th quarter valued at approximately $25,871,000. 45.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on CLBT. JPMorgan Chase & Co. lowered their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating on the stock in a report on Friday, August 14th. Needham & Company LLC reduced their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating on the stock in a report on Friday, August 14th. Weiss Ratings cut shares of Cellebrite DI from a "sell (d+)" rating to a "sell (d)" rating in a research note on Thursday, August 27th. DA Davidson dropped their price objective on shares of Cellebrite DI from $22.00 to $15.00 and set a "buy" rating for the company in a report on Friday, August 14th. Finally, Lake Street Capital cut their price objective on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.70.

Cellebrite DI Stock Up 2.8%

CLBT stock opened at $11.94 on Friday. Cellebrite DI Ltd. has a 52 week low of $9.58 and a 52 week high of $19.98. The firm has a market capitalization of $2.98 billion, a P/E ratio of 54.28, a price-to-earnings-growth ratio of 1.78 and a beta of 1.15. The company has a fifty day simple moving average of $14.10 and a two-hundred day simple moving average of $13.70.

Insider Buying and Selling at Cellebrite DI

In related news, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer owned 334,219 shares in the company, valued at approximately $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Thomas Hogan sold 139,713 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $15.39, for a total value of $2,150,183.07. Following the sale, the chief executive officer directly owned 790,548 shares in the company, valued at $12,166,533.72. The trade was a 15.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 329,658 shares of company stock worth $4,970,967 in the last 90 days. 5.70% of the stock is currently owned by insiders.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.